Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Technology Assessment	NCIT_C15335	[Technology assessment (TA) arose in the mid-1960s from an appreciation of the critical role of technology in modern society and its potential for unintended, and sometimes harmful, consequences. TA was conceived as a way to identify the desirable first-order, intended effects of technologies as well as the higher-order, unintended social, economic and environmental effects. TA methodology draws upon a variety of analytical, evaluative and planning techniques. Among these are systems analysis, cost-benefit analysis, consensus methods (e.g., Delphi method), engineering feasibility studies, clinical trials, market research, technological forecasting, and others. TA practitioners and policy makers recognized that TA is evolving, flexible, and should be tailored to the task (Brooks and Bowers 1970 and U.S. Congress, Office of Technology Assessment 1977).]
Grade 4 Ventricular Tachycardia, CTCAE	NCIT_C54900	[Life-threatening consequences; hemodynamic compromise]
PRETEXT Stage 2 Hepatoblastoma	NCIT_C7140	[An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 2 adjoining quadrants; 2 adjoining quadrants are free of tumor. (from PDQ 2004)]
Grade 4 Wolff-Parkinson-White Syndrome, CTCAE	NCIT_C54901
Thoracotomy	NCIT_C15337	[A surgical procedure in which an large incision is made into the chest wall, for the purpose of accessing organs inside the thoracic cavity.]
PRETEXT Stage 3 Hepatoblastoma	NCIT_C7141	[An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 3 adjoining quadrants or 2 nonadjoining quadrants; 1 quadrant or 2 nonadjoining quadrants are free of tumor. (from PDQ 2004)]
Tissue Collection	NCIT_C15339	[A repository of the tissue specimen, cells or cell lines, for experimental purpose. It can be from different diseases or different parts of the body.]
Posterior Pituitary Gland Neoplasm	NCIT_C7157	[A low-grade neoplasm that arises from the neurohypophysis. It includes the granular cell tumor of the sellar region, pituicytoma, spindle cell oncocytoma, and sellar ependymoma.]
Pituitary Gland Neoplasm	NCIT_C3330	[A benign or malignant neoplasm affecting the pituitary gland. The vast majority are adenomas arising from the anterior lobe of the pituitary gland.]
Primary Central Nervous System Neoplasm	NCIT_C102871	[A benign or malignant neoplasm that arises from the brain or the spinal cord.]
Smoothened Homolog	NCIT_C29980	[Smoothened homolog (787 aa, ~86 kDa) is encoded by the human SMO gene. This protein plays a role in the modulation of hedgehog signaling pathways.]
Subepidermal Nodular Fibrosis	NCIT_C7159
Ibritumomab Tiuxetan	NCIT_C29981	[An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.]
ALVAC-CEA (6D)-B7.1 Vaccine	NCIT_C29982	[A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-CEA (6D)-B7.1 vaccine expresses both a highly immunogenic analogue (6D) of the immunodominant epitope of carcinoembryonic antigen (CEA) and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28. This agent was designed to stimulate host immune responses against tumor cells that express CEA. (NCI04)]
ALVAC-CEA Vaccine	NCIT_C1648	[A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types.]
Fluorouracil/Interferon alpha/Interleukin-2/Leucovorin Calcium	NCIT_C29984
Fluorouracil	NCIT_C505	[An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.]
Leucovorin Calcium	NCIT_C607	[An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs. Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)]
Interleukin-1-beta New Formulation	NCIT_C29985	[An aqueous therapeutic analogue of the endogenous cytokine interleukin-1-beta (IL-1-beta). Produced mainly by monocytes, endogenous IL-1-beta plays a role in hematopoiesis, is a potent stimulator of T-cell activity, and may promote or inhibit tumor growth, depending on tumor type. (NCI04)]
Recombinant Interleukin-1	NCIT_C586	[A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-1 (IL-1). Produced mainly by monocytes, endogenous IL-1 plays a role in hematopoiesis, is a potent stimulator of T-cell activity, may promote or inhibit tumor growth, depending on tumor type. (NCI04)]